Abstract
Backgrounds
Gallbladder carcinoma (GBC) is an aggressive neoplasm, and resection is the only curative modality. Recurrence frequently occurs after the curative resection of advanced GBC. Adjuvant treatment, particularly radiotherapy, is recommended and is used without any evidence of a beneficial effect. The aim of this study was to characterize patterns of recurrence and to identify the factors that influence recurrence and the efficacy of adjuvant therapy after the curative resection of GBC.
Methods
The records of patients that underwent surgical resection with curative intent for gallbladder carcinoma from October 1994 and August 2007 were retrospectively reviewed. Recurrence patterns, times to recurrence, and survival rates were analyzed. Sites of recurrence were identified retrospectively and categorized as locoregional or distant.
Results
One hundred sixty-six patients underwent surgical resection with curative intent for gallbladder adenocarcinoma. The 5-year recurrence rates of stages IA, IB, IIA, and IIB patients were 0%, 24.3%, 44.9%, and 58.3%, retrospectively. Positivity for lymph node metastases was found to have predictive significance for disease-free survival (p = 0.009). Regional lymph node recurrence (27.7%) was observed most frequently. There was no significant disease-free survival rates between the no adjuvant therapy and the adjuvant therapy groups.
Conclusions
The regional lymph nodes and the liver were found to be the most common sites of recurrence after curative resection. Lymph node metastases were identified as an independent predictor of tumor recurrence by multivariate analysis. Based on the disease-free survivals observed in this study, the authors find it would be difficult to advocate the routine use of adjuvant radiotherapy and/or chemotherapy
Similar content being viewed by others
References
Destoll M. Rationis mendendi. In Batavorum L, Haak ET Socios A, Honkoop J, ed. Nosocomio practico vendobonensi, Part I, 1788.
Fong Y, Malhotra S. Gallbladder cancer: recent advances and current guidelines for surgical therapy. Adv Surg 2001;35:1–20.
Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg 1994;219:275–280.
Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978;147:929–942.
Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 2000;232:557–569.
Tsukada K, Hatakeyama K, Kurosaki I, Uchida K, Shirai Y, Muto T, Yoshida K. Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. Surgery 1996;120:816–821.
Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 1996;224:639–646.
Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002;52:167–175.
Mahe M, Stampfli C, Romestaing P, Salerno N, Gerard JP. Primary carcinoma of the gall-bladder: potential for external radiation therapy. Radiother Oncol 1994;33:204–208.
Manfredi S, Benhamiche AM, Isambert N, Prost P, Jouve JL, Faivre J. Trends in incidence and management of gallbladder carcinoma: a population-based study in France. Cancer 2000;89:757–762.
Donohue JH. Present status of the diagnosis and treatment of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 2001;8:530–534.
Matsumoto Y, Fujii H, Aoyama H, Yamamoto M, Sugahara K, Suda K. Surgical treatment of primary carcinoma of the gallbladder based on the histologic analysis of 48 surgical specimens. Am J Surg 1992;163:239–245.
Taner CB, Nagorney DM, Donohue JH. Surgical treatment of gallbladder cancer. J Gastrointest Surg 2004;8:83–89; discussion 89.
Pitt HA, Dooley WC, Yeo CJ, Cameron JL. Malignancies of the biliary tree. Curr Probl Surg 1995;32:1–90.
Kim HS, Lee JH, Chung JB, Song SY, Kang JK, Park IS, Choi JS, Kim BR. Survival factors of gallbladder carcinoma. Korean J Gastroenterol 2000;35:367–377.
Aramaki M, Matsumoto T, Shibata K, Himeno Y, Yada K, Hirano S, Sasaki A, Kawano K, Kitano S. Factors influencing recurrence after surgical treatment for T2 gallbladder carcinoma. Hepatogastroenterology 2004;51:1609–1611.
Park JS, Yoon DS, Kim KS, Choi JS, Lee WJ, Chi HS, Kim BR. Actual recurrence patterns and risk factors influencing recurrence after curative resection with stage II gallbladder carcinoma. J Gastrointest Surg 2007;11:631–637.
Shirai Y, Yoshida K, Tsukada K, Muto T, Watanabe H. Radical surgery for gallbladder carcinoma. Long-term results. Ann Surg 1992;216:565–568.
Yamaguchi K, Chijiiwa K, Saiki S, Nishihara K, Takashima M, Kawakami K, Tanaka M. Retrospective analysis of 70 operations for gallbladder carcinoma. Br J Surg 1997;84:200–204.
Chan SY, Poon RT, Lo CM, Ng KK, Fan ST. Management of carcinoma of the gallbladder: a single-institution experience in 16 years. J Surg Oncol 2008;97:156–164.
Houry S, Schlienger M, Huguier M, Lacaine F, Penne F, Laugier A. Gallbladder carcinoma: role of radiation therapy. Br J Surg 1989;76:448–450.
Todoroki T, Iwasaki Y, Orii K, Otsuka M, Ohara K, Kawamoto T, Nakamura K. Resection combined with intraoperative radiation therapy (IORT) for stage IV (TNM) gallbladder carcinoma. World J Surg 1991;15:357–366.
Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer, II, Wolff RA, Charnsangavej C, Brown TD. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101:578–586.
Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167–176.
Pitt HA. Gallbladder cancer: what is an aggressive approach? Ann Surg 2005;241:395–396.
Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685–1695.
de Aretxabala X, Losada H, Mora J, Roa I, Burgos L, Yanez E, Quijada I, Roa JC. [Neoadjuvant chemoradiotherapy in gallbladder cancer]. Rev Med Chil 2004;132:51–57.
Todoroki T, Kawamoto T, Takahashi H, Takada Y, Koike N, Otsuka M, Fukao K. Treatment of gallbladder cancer by radical resection. Br J Surg 1999;86:622–627.
Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M. DeMatteo RP, Wagman R, Blumgart LH, Fong Y. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689–1700.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, W.S., Choi, D.W., You, D.D. et al. Risk Factors Influencing Recurrence, Patterns of Recurrence, and the Efficacy of Adjuvant Therapy After Radical Resection for Gallbladder Carcinoma. J Gastrointest Surg 14, 679–687 (2010). https://doi.org/10.1007/s11605-009-1140-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-009-1140-z